Potential drugs which activate nuclear factor E2-related factor 2 signaling to prevent diabetic cardiovascular complications: A focus on fumaric acid esters

Life Sciences

Volumn 134, Issue 1, 2015, Pages 56-62

  Zhou, Shanshan ^a   Jin, Jingpeng ^b   Bai, Tao ^a   Sachleben, Leroy R ^c   Cai, Lu ^a,c   Zheng, Yang ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^c University of Louisville School of Medicine   (United States)

Author keywords

Bardoxolone; Diabetic complications; Dimethyl fumarate; Nrf2; Oxidative stress; Sulforaphane

Indexed keywords

BARDOXOLONE; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; SULFORAPHANE; TRANSCRIPTION FACTOR NF E2; ZINC; ANTIOXIDANT; DERMATOLOGICAL AGENT; NFE2L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BROCCOLI; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG TARGETING; HUMAN; NONHUMAN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; METABOLISM; UPREGULATION;

ANIMALIA;

ANIMALS; ANTIOXIDANTS; DERMATOLOGIC AGENTS; DIABETIC CARDIOMYOPATHIES; FUMARATES; HUMANS; NF-E2-RELATED FACTOR 2; UP-REGULATION;

EID: 84934933231     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2015.05.015     Document Type: Review

References (77)

1. T.D. Filippatos, E.C. Rizos, I.F. Gazi, K. Lagos, D. Agouridis, D.P. Mikhailidis, M.S. Elisaf, Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study, Arch Med Sci. 9 (2013) 788-795.
2. E. Selvin, J. Coresh, S.H. Golden, F.L. Brancati, A.R. Folsom, M.W. Steffes, Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study, Arch. Intern. Med. 165 (2005) 1910-1916.
3. E. Selvin, M.W. Steffes, H. Zhu, K. Matsushita, L. Wagenknecht, J. Pankow, J. Coresh, F.L. Brancati, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N. Engl. J. Med. 362 (2010) 800-811.
4. S. Boudina, E.D. Abel, Diabetic cardiomyopathy revisited, Circulation 115 (2007) 3213-3223.
5. H. Monkemann, A.S. De Vriese, H.J. Blom, L.A. Kluijtmans, S.G. Heil, H.H. Schild, O. Golubnitschaja, Early molecular events in the development of the diabetic cardiomyopathy, Amino Acids 23 (2002) 331-336.
6. L. Cai, Y.J. Kang, Oxidative stress and diabetic cardiomyopathy: a brief review, Cardiovasc. Toxicol. 1 (2001) 181-193.
7. M. Hamblin, D.B. Friedman, S. Hill, R.M. Caprioli, H.M. Smith, M.F. Hill, Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy, J. Mol. Cell. Cardiol. 42 (2007) 884-895.
8. L. Cai, Y. Wang, G. Zhou, T. Chen, Y. Song, X. Li, Y.J. Kang, Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy, J. Am. Coll. Cardiol. 48 (2006) 1688-1697.
9. E. Adeghate, Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review, Mol. Cell. Biochem. 261 (2004) 187-191.
10. V.I. Lushchak, Free radicals, reactive oxygen species, oxidative stress and its classification, Chem. Biol. Interact. 224C (2014) 164-175.
11. T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.P. Hammes, I. Giardino, M. Brownlee, Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, Nature 404 (2000) 787-790.
12. T. Inoguchi, P. Li, F. Umeda, H.Y. Yu, M. Kakimoto, M. Imamura, T. Aoki, T. Etoh, T. Hashimoto, M. Naruse, H. Sano, H. Utsumi, H. Nawata, High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells, Diabetes 49 (2000) 1939-1945.
13. L. Cai, Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications, Curr. Med. Chem. 14 (2007) 2193-2203.
14. Y.H. Chen, S.J. Lin, M.W. Lin, H.L. Tsai, S.S. Kuo, J.W. Chen, M.J. Charng, T.C. Wu, L.C. Chen, P.Y.A. Ding, W.H. Pan, Y.S. Jou, L.Y. Chau, Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients, Hum. Genet. 111 (2002) 1-8.
15. X. Liu, J. Wei, D.H. Peng, M.D. Layne, S.F. Yet, Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice, Diabetes 54 (2005) 778-784.
16. Y. Zhao, L. Zhang, Y. Qiao, X. Zhou, G. Wu, L. Wang, Y. Peng, X. Dong, H. Huang, L. Si, X. Zhang, L. Zhang, J. Li, W. Wang, L. Zhou, X. Gao, Heme oxygenase-1 prevents cardiac dysfunction in streptozotocin-diabetic mice by reducing inflammation, oxidative stress, apoptosis and enhancing autophagy, PLoS One 8 (2013) e75927.
17. Z. Xia, Z. Guo, P.R. Nagareddy, V. Yuen, E. Yeung, J.H. McNeill, Antioxidant N-acetylcysteine restores myocardial Mn-SOD activity and attenuates myocardial dysfunction in diabetic rats, Eur. J. Pharmacol. 544 (2006) 118-125.
18. X. Shen, S. Zheng, N.S. Metreveli, P.N. Epstein, Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy, Diabetes 55 (2006) 798-805.
19. K. Iwata, T. Nishinaka, K. Matsuno, C. Yabe-Nishimura, Increased gene expression of glutathione peroxidase-3 in diabetic mouse heart, Biol. Pharm. Bull. 29 (2006) 1042-1045.
20. S. Matsushima, S. Kinugawa, T. Ide, H. Matsusaka, N. Inoue, Y. Ohta, T. Yokota, K. Sunagawa, H. Tsutsui, Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart, Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H2237-H2245.
21. K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, K. Igarashi, J.D. Engel, M. Yamamoto, Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain, Genes Dev. 13 (1999) 76-86.
22. A. Kobayashi, M.I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, T. Chiba, K. Igarashi, M. Yamamoto, Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate for proteasomal degradation of Nrf2, Mol. Cell. Biol. 24 (2004) 7130-7139.
23. T. Yamamoto, T. Suzuki, A. Kobayashi, J. Wakabayashi, J. Maher, H. Motohashi, M. Yamamoto, Physiological significance of reactive cysteine residues of keap1 in determining Nrf2 activity, Mol. Cell. Biol. 28 (2008) 2758-2770.
24. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, Y. Nabeshima, An Nrf2 small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements, Biochem. Biophys. Res. Commun. 236 (1997) 313-322.
25. R. Howden, Nrf2 and cardiovascular defense, Oxidative Med. Cell. Longev. 2013 (2013) 104308, http://dx.doi.org/10.1155/2013/104308.
26. A.K. Jain, A.K. Jaiswal, GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2, J. Biol. Chem. 282 (2007) 16502-16510.
27. F. Rizvi, S. Shukla, P. Kakkar, Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3beta/Fyn kinase axis during oxidative hepatocellular toxicity, Cell Death Dis. 5 (2014) e1153.
28. M. Mishra, Q. Zhong, R.A. Kowluru, Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy, Invest. Ophthalmol. Vis. Sci. 55 (2014) 7256-7265.
29. L. Wang, C. Zhang, Y. Guo, Z.Y. Su, Y. Yang, L. Shu, A.N. Kong, Blocking of JB6 cell transformation by tanshinone IIA: epigenetic reactivation of Nrf2 antioxidative stress pathway, AAPS J. 16 (2014) 1214-1225.
30. C. Zhang, Z.Y. Su, T.O. Khor, L. Shu, A.N. Kong, Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation, Biochem. Pharmacol. 85 (2013) 1398-1404.
31. H. Zhu, K. Itoh, M. Yamamoto, J.L. Zweier, Y. Li, Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: protection against reactive oxygen and nitrogen species-induced cell injury, FEBS Lett. 579 (2005) 3029-3036.
32. H. Zhu, Z. Jia, B.R. Misra, L. Zhang, Z. Cao, M. Yamamoto, M.A. Trush, H.P. Misra, Y. Li, Nuclear factor E2-related factor 2-dependent myocardiac cytoprotection against oxidative and electrophilic stress, Cardiovasc. Toxicol. 8 (2008) 71-85.
33. T. Inoguchi, P. Li, F. Umeda, H.Y. Yu, M. Kakimoto, M. Imamura, T. Aoki, T. Etoh, T. Hashimoto, M. Naruse, H. Sano, H. Utsumi, H. Nawata, High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells, Diabetes 49 (2000) 1939-1945.
34. P. Gao, L. Li, L. Ji, Y. Wei, H. Li, G. Shang, Z. Zhao, Q. Chen, T. Jiang, N. Zhang, Nrf2 ameliorates diabetic nephropathy progression by transcriptional repression of TGFbeta1 through interactions with c-Jun and SP1, Biochim. Biophys. Acta 1839 (2014) 1110-1120.
35. Z. Xu, Y. Wei, J. Gong, H. Cho, J.K. Park, E.R. Sung, H. Huang, L. Wu, C. Eberhart, J.T. Handa, Y. Du, T.S. Kern, R. Thimmulappa, A.J. Barber, S. Biswal, E.J. Duh, NRF2 plays a protective role in diabetic retinopathy in mice, Diabetologia 57 (2014) 204-213.
36. X.Q. He, H. Kan, L. Cai, Q. Ma, Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes, J. Mol. Cell. Cardiol. 46 (2009) 47-58.
37. Y. Bai, W.P. Cui, Y. Xin, X. Miao, M.T. Barati, C. Zhang, Q. Chen, Y. Tan, T.X. Cui, Y. Zheng, L. Cai, Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation, J. Mol. Cell. Cardiol. 57 (2013) 82-95.
38. Y. Tan, T. Ichikawa, J. Li, Q. Si, H. Yang, X. Chen, C.S. Goldblatt, C.J. Meyer, X. Li, L. Cai, T. Cui, Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo, Diabetes 60 (2011) 625-633.
39. B. Li, S. Liu, L. Miao, L. Cai, Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy, Exp. Diabetes Res. 2012 (2012) 216512.
40. K. Yoh, A. Hirayama, K. Ishizaki, A. Yamada, M. Takeuchi, S. Yamagishi, N. Morito, T. Nakano, M. Ojima, H. Shimohata, K. Itoh, S. Takahashi, M. Yamamoto, Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice, Genes Cells 13 (2008) 1159-1170.
41. T. Jiang, Z. Huang, Y. Lin, Z. Zhang, D. Fang, D.D. Zhang, The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy, Diabetes 59 (2010) 850-860.
42. Z. Zhao, Y. Chen, J. Wang, P. Sternberg, M.L. Freeman, H.E. Grossniklaus, J. Cai, Agerelated retinopathy in NRF2-deficient mice, PLoS One 6 (2011) e19456.
43. Y. Wei, J. Gong, T. Yoshida, C.G. Eberhart, Z. Xu, P. Kombairaju, M.B. Sporn, J.T. Handa, E.J. Duh, Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury, Free Radic. Biol. Med. 51 (2011) 216-224.
44. W.S. Jeong, M. Jun, A.N.T. Kong, Nrf2: a potential molecular target for cancer chemoprevention by natural compounds, Antioxid. Redox Signal. 8 (2006) 99-106.
45. C. Deng, Z. Sun, G. Tong, W. Yi, L. Ma, B. Zhao, L. Cheng, J. Zhang, F. Cao, D. Yi, Alphalipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/reperfusion injury through activation of PI3K/Akt/Nrf2 pathway, PLoS One 8 (2013) e58371.
46. Y. Zhang, M. Sano, K. Shinmura, K. Tamaki, Y. Katsumata, T. Matsuhashi, S. Morizane, H. Ito, T. Hishiki, J. Endo, H. Zhou, S. Yuasa, R. Kaneda, M. Suematsu, K. Fukuda, 4-Hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf2-dependent pathway, J. Mol. Cell. Cardiol. 49 (2010) 576-586.
47. J.W. Calvert, S. Jha, S. Gundewar, J.W. Elrod, A. Ramachandran, C.B. Pattillo, C.G. Kevil, D.J. Lefer, Hydrogen sulfide mediates cardioprotection through Nrf2 signaling, Circ. Res. 105 (2009) 365-374.
48. Y.H. Wang, W.X. Sun, B. Du, X. Miao, Y. Bai, Y. Xin, Y. Tan, W.P. Cui, B. Liu, T.X. Cui, P.N. Epstein, Y.W. Fu, L. Cai, Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NFkappa B, Am. J. Physiol. Heart Circ. Physiol. 304 (2013) H567-H578.
49. Z.F. Luo, W. Qi, B. Feng, J. Mu, W. Zeng, Y.H. Guo, Q. Pang, Z.L. Ye, L. Liu, F.H. Yuan, Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome, Life Sci. 88 (2011) 512-520.
50. H. Zheng, S.A. Whitman, W. Wu, G.T. Wondrak, P.K. Wong, D. Fang, D.D. Zhang, Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy, Diabetes 60 (2011) 3055-3066.
51. P. Palsamy, S. Subramanian, Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling, Biochim. Biophys. Acta 1812 (2011) 719-731.
52. T.A. Shapiro, J.W. Fahey, A.T. Dinkova-Kostova, W.D. Holtzclaw, K.K. Stephenson, K.L. Wade, L. Ye, P. Talalay, Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study, Nutr. Cancer 55 (2006) 53-62.
53. L. Ye, A.T. Dinkova-Kostova, K.L. Wade, Y. Zhang, T.A. Shapiro, P. Talalay, Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans, Clin. Chim. Acta 316 (2002) 43-53.
54. Z. Bahadoran, M. Tohidi, P. Nazeri, M. Mehran, F. Azizi, P. Mirmiran, Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial, Int. J. Food Sci. Nutr. 63 (2012) 767-771.
55. Q.Q. Wu, Y. Wang, M. Senitko, C. Meyer, W.C. Wigley, D.A. Ferguson, E. Grossman, J. Chen, X.J. Zhou, J. Hartono, P. Winterberg, B. Chen, A. Agarwal, C.Y. Lu, Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1, Am. J. Physiol. Renal Physiol. 300 (2011) F1180-F1192.
56. Y. Ding, R.D. Stidham, R. Bumeister, I. Trevino, A. Winters, M. Sprouse, M. Ding, D.A. Ferguson, C.J. Meyer, W.C. Wigley, R. Ma, The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells, Kidney Int. 83 (2013) 845-854.
57. M.A. Aminzadeh, S.A. Reisman, N.D. Vaziri, M. Khazaeli, J. Yuan, C.J. Meyer, The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease, Xenobiotica 44 (2014) 570-578.
58. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, E.B. Grossman, M. Krauth, S. Ruiz, P. Audhya, H. Christ-Schmidt, J. Wittes, D.G. Warnock, B.S. Investigators, Bardoxolone methyl and kidney function in CKD with type 2 diabetes, N. Engl. J. Med. 365 (2011) 327-336.
59. D. de Zeeuw, T. Akizawa, P. Audhya, G.L. Bakris, M. Chin, H. Christ-Schmidt, A. Goldsberry, M. Houser, M. Krauth, H.J. Lambers Heerspink, J.J. McMurray, C.J. Meyer, H.H. Parving, G. Remuzzi, R.D. Toto, N.D. Vaziri, C. Wanner, J. Wittes, D. Wrolstad, G.M. Chertow, B.T. Investigators, Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease, N. Engl. J. Med. 369 (2013) 2492-2503.
60. B. Li, W. Cui, Y. Tan, P. Luo, Q. Chen, C. Zhang, W. Qu, L. Miao, L. Cai, Zinc is essential for the transcription function of Nrf2 in human renal tubule cells in vitro and mouse kidney in vivo under the diabetic condition, J. Cell. Mol. Med. 18 (2014) 895-906.
61. K.C. de Sena, R.F. Arrais, M. das Gracas Almeida, D.M. de Araujo, M.M. dos Santos, V.T. de Lima, L. de Fatima Campos Pedrosa, Effects of zinc supplementation in patients with type 1 diabetes, Biol. Trace Elem. Res. 105 (2005) 1-9.
62. R. Gupta, V.K. Garg, D.K. Mathur, R.K. Goyal, Oral zinc therapy in diabetic neuropathy, J. Assoc. Physicians India 46 (1998) 939-942.
63. R.C. Seet, C.Y. Lee, E.C. Lim, A.M. Quek, H. Huang, S.H. Huang, W.F. Looi, L.H. Long, B. Halliwell, Oral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels, Atherosclerosis 219 (2011) 231-239.
64. W. Schweckendiek, Treatment of Psoriasis vulgaris, Med. Monatsschr. 13 (1959) 103-104.
65. S. Ruggieri, C. Tortorella, C. Gasperini, Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis, Ther. Clin. Risk Manag. 10 (2014) 229-239.
66. R.A. Linker, D.H. Lee, S. Ryan, A.M. van Dam, R. Conrad, P. Bista, W. Zeng, X. Hronowsky, A. Buko, S. Chollate, G. Ellrichmann, W. Bruck, K. Dawson, S. Goelz, S. Wiese, R.H. Scannevin, M. Lukashev, R. Gold, Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway, Brain 134 (2011) 678-692.
67. R.H. Scannevin, S. Chollate, M.Y. Jung, M. Shackett, H. Patel, P. Bista, W. Zeng, S. Ryan, M. Yamamoto, M. Lukashev, K.J. Rhodes, Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway, J. Pharmacol. Exp. Ther. 341 (2012) 274-284.
68. S. Kalinin, P.E. Polak, S.X. Lin, D. Braun, M. Guizzetti, X. Zhang, I. Rubinstein, D.L. Feinstein, Dimethyl fumarate regulates histone deacetylase expression in astrocytes, J. Neuroimmunol. 263 (2013) 13-19.
69. R. Gold, L. Kappos, D.L. Arnold, A. Bar-Or, G. Giovannoni, K. Selmaj, C. Tornatore, M.T. Sweetser, M. Yang, S.I. Sheikh, K.T. Dawson, D.S. Investigators, Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, N. Engl. J. Med. 367 (2012) 1098-1107.
70. R.J. Fox, D.H. Miller, J.T. Phillips, M. Hutchinson, E. Havrdova, M. Kita, M. Yang, K. Raghupathi, M. Novas, M.T. Sweetser, V. Viglietta, K.T. Dawson, C.S. Investigators, Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis, N. Engl. J. Med. 367 (2012) 1087-1097.
71. A. Bar-Or, R. Gold, L. Kappos, D.L. Arnold, G. Giovannoni, K. Selmaj, J. O'Gorman, M. Stephan, K.T. Dawson, Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study, J. Neurol. 260 (2013) 2297-2305.
72. R. Kunze, A. Urrutia, A. Hoffmann, H. Liu, X. Helluy, M. Pham, S. Reischl, T. Korff, H.H. Marti, Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity, Exp. Neurol. 266C (2015) 99-111.
73. X. Jing, H. Shi, C. Zhang, M. Ren, M. Han, X. Wei, X. Zhang, H. Lou, Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity, Neuroscience 286 (2015) 131-140.
74. C.M. Ha, S. Park, Y.K. Choi, J.Y. Jeong, C.J. Oh, K.H. Bae, S.J. Lee, J.H. Kim, K.G. Park, D.Y. Jun, I.K. Lee, Activation of Nrf2 by dimethyl fumarate improves vascular calcification, Vasc. Pharmacol. 63 (2014) 29-36.
75. H. Ashrafian, G. Czibik, M. Bellahcene, D. Aksentijevic, A.C. Smith, S.J. Mitchell, M.S. Dodd, J. Kirwan, J.J. Byrne, C. Ludwig, H. Isackson, A. Yavari, N.B. Stottrup, H. Contractor, T.J. Cahill, N. Sahgal, D.R. Ball, R.I. Birkler, I. Hargreaves, D.A. Tennant, J. Land, C.A. Lygate, M. Johannsen, R.K. Kharbanda, S. Neubauer, C. Redwood, R. de Cabo, I. Ahmet, M. Talan, U.L. Gunther, A.J. Robinson, M.R. Viant, P.J. Pollard, D.J. Tyler, H. Watkins, Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway, Cell Metab. 15 (2012) 361-371.
76. J. Silhavy, V. Zidek, P. Mlejnek, V. Landa, M. Simakova, H. Strnad, O. Oliyarnyk, V. Skop, L. Kazdova, T. Kurtz, M. Pravenec, Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats, PLoS One 9 (2014) e101906.
77. C.J. Oh, S. Park, J.Y. Kim, H.J. Kim, N.H. Jeoung, Y.K. Choi, Y. Go, K.G. Park, I.K. Lee, Dimethylfumarate attenuates restenosis after acute vascular injury by cell-specific and Nrf2-dependent mechanisms, Redox Biol. 2 (2014) 855-864.